Dovitinib (Standard)

Overview

Dovitinib (Standard) is the analytical standard of Dovitinib. This product is intended for research and analytical applications. Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3 , c-Kit , CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Others | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > FLT3 | Products > Signaling Pathways > c-Kit | Products > Signaling Pathways > FGFR | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > c-Fms

Product Information

• Catalog No.: HY-50905R
• CAS No.: 405169-16-6
• Molecular Formula: C21H21FN6O
• Molecular Weight: 392.43
• Purity: 98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source